Sep 2026· American Journal of Transplantation· 0 citations· 12 references
Medicine
TL;DR
The use of multiomics as a hypothesis-generating tool to guide next-generation donor-pig design and adjust immunosuppression is summarized, while exploring its contribution to the diagnosis of xenograft rejection.
Abstract
Since the first successful allograft in 1954, the field has sought a method to monitor the delicate balance between immunosuppression and graft function. Over the last 20 years, multiomic approaches have provided increasingly detailed molecular characterization of the immunologic and physiological processes underlying graft injury. Xenotransplantation, now in its clinical infancy, has been a rapid adopter of multiomic analysis and benefited from lessons learned in allotransplantation. In our first edition of the AJT XenoPulse, we reviewed the progress made in living recipients and the clinical applications of xenotransplantation across cardiac, renal, and hepatic grafts. This second edition summarized the use of multiomics as a hypothesis-generating tool to guide next-generation donor-pig design and adjust immunosuppression, while exploring its contribution to the diagnosis of xenograft rejection. Across organs, emerging studies highlighted prominent innate immune responses and illustrated how tools developed in allotransplantation may need to be adapted to the cross-species setting. These findings are beginning to define a path toward integrated, xeno-specific diagnostics for clinical monitoring and trial design, although most signatures remain associative and will require analytical and clinical validation.
Clinical xenotransplantation offers a conceptually unlimited supply of donor organs, owing to transformative advances in gene-editing technologies. However, the pharmacological and physiological distinctions between allo- and xenotransplantation pose a major challenge. Unlike allografts, xenografts simultaneously trigg...
Kyu-Hyun Han, J. Yang· Clinical transplantation and...· 0 citations
Advanced heart failure affects over 6 million adults in the United States alone. Orthotopic heart transplantation remains the definitive treatment, with over 90% one-year survival and meaningful gains in functional status and quality of life. The therapy is, however, constrained by an intractable supply problem. For de...
A. Abdelrehim, D. Hurst, W. H. Gray et al.· Frontiers in Transplantation· 0 citations
ABSTRACT Lung transplantation is the only long‐lasting life‐saving treatment for patients with end‐stage pulmonary disease, but the ever‐growing shortage of suitable donor organs leads to high mortality rates of the afflicted patients. Xenotransplantation, the transplantation of organs across species, has emerged as a...
N. Roters, Niveditha Varma, R. Ramm et al.· Xenotransplantation· 0 citations
This case shows that porcine kidney xenotransplantation can provide prolonged renal support and be discontinued without clinically significant allosensitisation or zoonotic infection.
L. Riella, Thiago J. Borges, Ivy A. Rosales et al.· The Lancet· 2 citations
The four-decade evolution of genetically engineered (GE) pigs from the first α-1,3-galactosyltransferase knockout in 2003 to today's 10-gene and 69-edit donors has progressively dismantled the immunologic barriers to xenotransplantation. Hyperacute and acute humoral rejection have been largely overcome through triple k...
Jeong Ho Hwang· Clinical transplantation and...· 0 citations
Infection-related risks remain a major concern in xenotransplantation and require continued vigilance as the field progresses toward clinical application. Xenozoonosis is of particular concern, especially in relation to donor-derived porcine viruses such as porcine endogenous retroviruses, porcine cytomegalovirus, porc...